Sanofi Returns Rights of Diabetes Drug 'Epeglenatide' to Hanmi Pharm

[Asia Economy Reporter Cho Hyun-ui] Sanofi has decided to finally return the rights of the diabetes drug 'Epeglenatide,' for which it had acquired technology from Hanmi Pharmaceutical, back to Hanmi Pharmaceutical.

According to Hanmi Pharmaceutical on the 9th, Sanofi notified its intention to return the rights last May and made the final decision on this matter yesterday (local time).

Hanmi Pharmaceutical will not return the contract payment of 200 million euros (approximately 264.3 billion KRW) received from Sanofi.

Hanmi Pharmaceutical will take over all five Phase 3 clinical trial data of Epeglenatide conducted by Sanofi. Among these, one trial scheduled to be completed in October will be finalized by Hanmi Pharmaceutical.

Hanmi Pharmaceutical plans to explore new opportunities such as investigating indications other than diabetes treatment, combination therapy research, and establishing new partnerships.

A Hanmi Pharmaceutical official stated, "Although the development of Epeglenatide as a diabetes treatment will be discontinued, we will seek new opportunities in the treatment of various other metabolic syndrome diseases."